Vladimir Vexler - Jan 4, 2022 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Vladimir Vexler
Stock symbol
CHRS
Transactions as of
Jan 4, 2022
Transactions value $
$0
Form type
4
Date filed
1/6/2022, 06:48 PM
Next filing
Jan 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRS Common Stock Award $0 +40K +53.22% $0.00 115K Jan 4, 2022 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Award $0 +80K $0.00 80K Jan 4, 2022 Common Stock 80K $15.94 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 4 of each year, with the first 1/3 vesting on January 4, 2023 and with the RSUs being fully vested on January 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F2 Includes 112,083 RSUs.
F3 Includes 1,768 shares acquired on November 15, 2021, pursuant to Issuer's employee stock purchase plan.
F4 The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.